ratner ej the lancet p106 jan 14 2978 taught us how
strike 1
Curr Opin Immunol. 2018 Dec;55:89-96. doi: 10.1016/j.coi.2018.09.016. Epub 2018 Nov 15.
Bridging the gap between vaccination with Bacille Calmette-Guérin (BCG) and immunological tolerance: the cases of type 1 diabetes and multiple sclerosis.
Abstract
At the end of past century, when the prevailing view was that treatment of autoimmunity required immune suppression, experimental evidence suggested an approach of immune-stimulation such as with the BCG vaccine in type 1 diabetes (T1D) and multiple sclerosis (MS). Translating these basic studies into clinical trials, we showed the following: BCG harnessed the immune system to 'permanently' lower blood sugar, even in advanced T1D; BCG appeared to delay the disease progression in early MS; the effects were long-lasting (years after vaccination) in both diseases. The recently demonstrated capacity of BCG to boost glycolysis may explain both the improvement of metabolic indexes in T1D, and the more efficient generation of inducible regulatory T cells, which counteract the autoimmune attack and foster repair mechanisms.
strike two
he does not see thst BCG Is avsislsble to us all in need so that the may be better snd less susceptible to harm from corona virus
surely you jest
the boys from fort detrick sre working to increase the virus killl rate snd make it as transmisdible as the measles giving drop dead meaning instesd of mania
The corps is racing against the spread of the coronavirus to turn empty buildings in cities across the United States into high-quality COVID-19 treatment centers before the virus reaches its peak in each metropolis, Lt. Gen. Todd Semonite told reporters. To achieve this, he said the corps had come up with “a standard design” to rapidly convert hotels and similar structures into medical facilities.
Curr Opin Immunol. 2018 Dec;55:89-96. doi: 10.1016/j.coi.2018.09.016. Epub 2018 Nov 15.
Bridging the gap between vaccination with Bacille Calmette-Guérin (BCG) and immunological tolerance: the cases of type 1 diabetes and multiple sclerosis.
Abstract
At the end of past century, when the prevailing view was that treatment of autoimmunity required immune suppression, experimental evidence suggested an approach of immune-stimulation such as with the BCG vaccine in type 1 diabetes (T1D) and multiple sclerosis (MS). Translating these basic studies into clinical trials, we showed the following: BCG harnessed the immune system to 'permanently' lower blood sugar, even in advanced T1D; BCG appeared to delay the disease progression in early MS; the effects were long-lasting (years after vaccination) in both diseases. The recently demonstrated capacity of BCG to boost glycolysis may explain both the improvement of metabolic indexes in T1D, and the more efficient generation of inducible regulatory T cells, which counteract the autoimmune attack and foster repair mechanisms.
No comments:
Post a Comment